Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Eli Lilly is doubling down on manufacturing investments announcing a US3 billion expansion of its Wisconsin facility ...

Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to ...

A national medical firm has announced it will launch a $3 billion expansion of its Kenosha County facility and will bring 750 ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...